【摘要】 为评价普罗布考调脂作用，将７２例原发性高脂血症者随机分为２组，每组３６例，Ｐ组服普罗布考（Ｐｒｏｂｕｃｏｌ）１．０ｇ／ｄ；Ｆ组服非诺贝特（Ｆｅｎｏｆｉｂｒａｔｅ）０．３ｇ／ｄ，疗程均为３个月。治疗结束时Ｐ组和Ｆ组服药前后比较，血清总蛋固醇（ＴＣ）降低３７１％和２７３％，低密度脂蛋白胆固醇（ＬＤＬＣ）降低３９４％和３２６％，甘油三酯降低１７５％和４８６％，高密度脂蛋白胆固醇（ＨＤＬＣ）Ｐ组降低２８０％，Ｆ组升高１９７％，Ｆ组降低脂蛋白（ａ）１９３％。结果表明，Ｐ组调脂作用ＴＣ，ＬＤＬＣ优于Ｆ组，ＴＧ及ＨＤＬＣ逊于Ｆ组。两组副反应情况类似，但Ｐ组程度较轻更多还原

【Abstract】 In order to evaluate the blood lipid regulating effect of probucol, 72 patients with primary hyperlipidemia were randomly divided into two groups of 36 each. Patients in group P took probucol(1.0g/day) and in group F took fenofibrate (0.3g/day). At the end of three monthstrial,their effects were compared: the serum level of total cholesterol(TC) was reduced by 37.1% and 27.3% respectively ( P < 0.05 ), triglyceride(TG) was reduced by 17.5% and 48.6% respectively ( P <0.05), and low density cholesterol(LDL C) was decreased by 39.4% and 32.6% respectively. The serum level of high density cholesterol(HDL C) was decreased by 28.0% in cases taking probucol and increased by 19.7% in cases using fenofibrate. The serum level of lipoprotein(a) was reduced by 19.3% with fenofibrate. A comparison between the two groups in the improvement of TC and LDL C, showed that the effect of probucol was superior to that of fenofibrate while in TG and HDL C, the effect of probucol was inferior. The results indicated that probucol is a safe, effective and tolerable lipid modulator.更多还原